Douglas Bratton Net Worth

Douglas Bratton biography

Douglas K. Bratton serves as Independent Director of the Company. Douglas K. Bratton has served as a member of our Board of Directors since January 2004 and was the Chairman of our Board from January 2004 until August 2018. Mr. Bratton is the Founder, President and Chief Investment Officer of Crestline Investors, an institutional alternative investment management firm. Mr. Bratton is also sole director of Bratton Capital, Inc., which is the general partner of Bratton Capital Management L.P. Mr. Bratton has been an investment professional specializing in alternative asset strategies since 1983 and has managed assets on behalf of the Bass family of Fort Worth, Texas, since 1988. Mr. Bratton received a B.S. from North Carolina State University and an M.B.A with Honors from Duke University. Mr. Bratton has served on the board of directors of Bounty Minerals Corporation, a private company, since 2014, and the Board of Visitors of Duke University’s Fuqua School of Business since 2013. Our Board believes that Mr. Bratton’s business experience, as well as his strong finance and management background, qualifies him to serve on our Board of Directors.

What is the salary of Douglas Bratton?

As the Independent Director of Aquestive Therapeutics Inc, the total compensation of Douglas Bratton at Aquestive Therapeutics Inc is $104,497. There are 8 executives at Aquestive Therapeutics Inc getting paid more, with A. Mark Schobel having the highest compensation of $7,575,660.

How old is Douglas Bratton?

Douglas Bratton is 61, he's been the Independent Director of Aquestive Therapeutics Inc since 2018. There are 12 older and 9 younger executives at Aquestive Therapeutics Inc. The oldest executive at Aquestive Therapeutics Inc is Gregory Brown, 66, who is the Independent Director.

What's Douglas Bratton's mailing address?

Douglas's mailing address filed with the SEC is C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN, NJ, 07059.

Insiders trading at Aquestive Therapeutics Inc

Over the last 6 years, insiders at Aquestive Therapeutics Inc have traded over $1,898,648 worth of Aquestive Therapeutics Inc stock and bought 370,463 units worth $3,088,399 . The most active insiders traders include Marco Taglietti, Nancy Lurker et Alexander Mark Schobel. On average, Aquestive Therapeutics Inc executives and independent directors trade stock every 36 days with the average trade being worth of $77,928. The most recent stock trade was executed by Alexander Mark Schobel on 15 March 2024, trading 50,000 units of AQST stock currently worth $300,000.

What does Aquestive Therapeutics Inc do?

aquestive therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. our initial focus, supported by our current approved products and late stage pipeline, is to address immediate cns challenges.

Aquestive Therapeutics Inc executives and stock owners

Aquestive Therapeutics Inc executives and other stock owners filed with the SEC include:

• A. Mark Schobel,
  Chief Innovation and Technology Officer
• Keith Kendall,
  President, Chief Executive Officer, Director
• Daniel Barber,
  Chief Operating Officer, Senior Vice President
• John Maxwell,
  Senior Vice President, Chief Financial Officer
• Keith J. Kendall,
  CEO, Pres & Director
• Daniel Barber,
  Sr. VP & COO
• Santo Costa,
  Independent Chairman of the Board
• James Scibetta,
  Independent Director
• Douglas Bratton,
  Independent Director
• Nancy Lurker,
  Independent Director
• Gregory Brown,
  Independent Director
• John Cochran,
  Vice Chairman of the Board
• Gary Slatko,
  Senior Vice President, Chief Medical Officer
• Kenneth Marshall,
  Senior Vice President - Chief Commercial Officer
• Peter Boyd,
  Senior Vice President - Business Process and Information Technology
• Theresa Wood,
  Senior Vice President - Human Resources and Organizational Development
• Lori Braender,
  Senior Vice President - General Counsel, Chief Compliance Officer and Corporate Secretary
• Dr. Gary H. Slatko M.D., MBA,
  Sr. VP & Chief Medical Officer
• Kenneth W. Marshall,
  Sr. VP & Chief Commercial Officer
• Peter E. Boyd,
  Sr. VP of Bus. Process & Information Technology
• Dr. Eric Dadey Ph.D.,
  Sr. Vice-Pres of R&D
• Theresa Wood,
  Sr. VP of HR & Organizational Devel.
• Lori J. Braender Esq.,
  Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Alexander Mark Schobel,
  Chief Innovation & Technology Officer
• A. Ernest Toth Jr.,
  Sr. VP & CFO
• Timothy E Morris,
  
• Ken W. Marshall,
  SVP, Chief Commercial Officer
• Marco Taglietti,
  
• Julie Krop,
  
• Douglas K Monoline Partners...,
  
• Cassie Jung,
  SVP, Operations
• Douglas K Mono Line Partner...,
  
• Kenneth Truitt,
  Chief Medical Officer
• A Ernest Jr Toth,
  SVP, Chief Financial Officer
• Carl N Kraus,
  Chief Medical Officer
• Stephen Wargacki,
  Chief Science Officer
• Abigail L. Jenkins,
  
• Sherry Korczynski,
  SVP Sales and Marketing